

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4267498

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT
EFFECTIVE DATE:	03/22/2016
CONVEYING PARTY DATA	
Name	Execution Date
NATIONAL CANCER CENTER	01/31/2017
RECEIVING PARTY DATA	
Name:	EUTILEX CO., LTD.
Street Address:	(GASAN-DONG) #1401, 25, GASAN DIGITAL 1-RO, GEUMCHEON-GU
City:	SEOUL
State/Country:	KOREA, REPUBLIC OF
Postal Code:	08594
PROPERTY NUMBERS Total: 7	
Property Type	Number
Application Number:	13861675
Application Number:	14739763
Application Number:	13861619
Application Number:	13861644
Application Number:	14739770
Application Number:	14639679
Application Number:	15053360
CORRESPONDENCE DATA	
Fax Number:	(815)654-5770
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	815-633-5300
Email:	rockmail@reinhardtllaw.com
Correspondent Name:	REINHART BOERNER VAN DEUREN P.C.
Address Line 1:	2215 PERRYGREEN WAY
Address Line 4:	ROCKFORD, ILLINOIS 61107
ATTORNEY DOCKET NUMBER:	510926
NAME OF SUBMITTER:	JEREMY R. BRIDGE
SIGNATURE:	/Jeremy R. Bridge/

DATE SIGNED:	02/09/2017
---------------------	------------

Total Attachments: 4
source=510926Assignment#page1.tif
source=510926Assignment#page2.tif
source=510926Assignment#page3.tif
source=510926Assignment#page4.tif

ASSIGNMENT OF PATENTS

THIS ASSIGNMENT OF PATENTS (the "Assignment") is made as of March 22, 2016 (the "Effective Date"), by and between NATIONAL CANCER CENTER, an organization of the country of Korea, and having a place of business of (Madu-dong) 323, Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 410-769, Republic of Korea (the "Assignor") and EUTILEX CO., LTD., an organization of the country of Korea, and having a place of business of (Gasam-dong) #1401, 25, Gasan digital 1-ro, Geumcheon-gu, Seoul, 08594, Republic of Korea (the "Assignee").

RECITALS

- A. Assignor is the owner of certain patents and/or patent applications (referred to as "the Patents").
- B. Assignee desires to obtain an assignment of all of Assignor's rights, title, and interest in and to the Patents from Assignor, and Assignor desires to grant an assignment of all of its rights, title, and interest in and to the Patents to Assignee.

AGREEMENT

NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and in consideration of the covenants and agreements set forth herein, Assignor and Assignee mutually agree as follows:

1. Definition. As used herein, the following term shall have the meanings set forth below:

1.1 Assigned Patents. The term "Assigned Patents" shall mean those patents and/or patent applications listed in Appendix A attached hereto and made a part hereof, as well as any and all patents maturing from a continuation, continuation-in-part, division, reissue, or reexamination of any Assigned Patents and regardless of whether such patent matures from a convention or non-convention application, or any other substitution, renewal, extension, addition, utility model, or other United States or foreign patent.

2. Assignment of the Assigned Patents. Subject to the terms, conditions, and limitations set forth herein, Assignor hereby assigns and transfers to Assignee, its successors, and assigns Assignor's entire rights, title, and interest in and to the Assigned Patents. The assignment of the Assigned Patents granted by Assignor to Assignee in this Agreement is granted free and clear of all security interests, liens, encumbrances, claims, or interests of any kind or nature.

3. Assignment of Accrued Enforcement Rights. Assignor hereby assigns and transfers to Assignee any and all claims or causes of action for infringement of any of the Assigned Patents that may have accrued prior to the effective date of this Assignment, together with the right to bring suit for and/or initiate any proceeding to collect any and all damages arising from said claims or causes of action.

4. Further Assurances. Assignor shall provide Assignee, its successors, and assigns, or their legal representatives, cooperation and assistance at Assignee's reasonable request and expense (including the execution and delivery of any and all affidavits, declarations, oaths, exhibits, assignments, powers of attorney, or other documentation as may be reasonably required): (i) in the prosecution and maintenance of the Assigned Patents; (ii) in the prosecution or defense of any interference, opposition, infringement, or other proceeding that may arise in connection with the Assigned Patents; and (iii) in the implementation or perfection of this Patent Assignment. Assignor agrees that he shall not assist or encourage, through action or inaction, any challenge to the validity, enforceability, or ownership of the Assigned Patents.

5. Representations and Warranties. Assignor expressly represents and warrants that: (i) Assignor has the sole and exclusive right to grant the assignment granted herein; (ii) to the best of its knowledge, no third party has any right, title, or interest in the Assigned Patents; (iii) Assignor has taken no action which may adversely affect Assignee's rights under this Patent Assignment; (iv) Assignor has not executed any assignments, sales, agreements, liens, mortgages, or encumbrances that conflict with the rights granted by this Patent Assignment; and (v) Assignor has the right to execute and enter into this Patent Assignment and to perform his obligations hereunder. Assignor warrants that, to the best of his knowledge, there are no circumstances that would: (i) render the Assigned Patents invalid or unenforceable; or (ii) render Assignee liable for patent infringement or trade secret misappropriation as a consequence of Assignee performing the activities permitted by this Patent Assignment or practice of the invention claimed in the Assigned Patents. Assignee represents that it has the power to enter into this Patent Assignment and perform the obligations assumed hereunder.

6. General Provisions.

6.1 Merger and Integration. This Assignment represents the entire understanding of the parties with respect to its subject matter and supersedes all prior agreements, written or oral, concerning the subject matter hereof, and may not be changed or modified in any regard except by an instrument in writing and signed by the parties hereto. No inference shall be drawn from any variance between this Assignment and any prior written negotiations or letters of intent with respect to, or drafts of, this Assignment. Each party acknowledges that no representations, inducements, promises, commitments or agreements, orally or otherwise, have been made by any party, or anyone acting on behalf of any party, which are not embodied herein.

6.2 Severability. It is expressly agreed that if any term or provision of this Assignment which is invalid or unenforceable in any jurisdiction, then such provision in such jurisdiction shall be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Assignment or affecting the validity or enforceability of any of the terms or provisions of this Assignment in any other jurisdiction.

6.3 No Waiver. Failure of any party at any time to require performance of any provision of this Agreement shall not affect the right of any party to

require full performance thereafter; a waiver by any party of a breach of any provision of this Agreement shall not constitute a modification of this Agreement or prevent that party from again enforcing such term or condition in the future with respect to subsequent events.

6.4 Relationship of the Parties. The relationship established between the parties by this Assignment shall be solely that of Assignor and Assignee. Neither party hereto shall have any right or shall attempt to enter into contracts or commitments on behalf of the other party or to bind the other party in any respect whatsoever.

6.5 Counterparts; Facsimile Signatures. This Assignment may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one document. This Assignment may be signed by facsimile, and facsimile signatures shall be binding, but the parties shall provide each other with originally signed copies of the Assignment as soon as possible thereafter.

6.6 Captions. The captions in this Assignment are intended solely as a matter of convenience and shall be given no effect in the construction or interpretation of this Assignment.

6.7 Recitals. The parties agree that the recitals prior to Section 1 of this Assignment are true and correct and are hereby incorporated herein by this reference.

6.8 Force Majeure. The parties agree that neither shall be deemed in default of its obligations under this Assignment to the extent that the performance of any such obligations shall have been prevented by circumstances outside of such party's control, including, but not limited to, acts of God, fire, riot, war or government actions, but only to the extent of the duration of the circumstances comprising the basis for the operation of this section. If a party believes that any one or more of the above occurrences or events will cause a delay or prevent its performance hereunder, that party shall promptly notify the other party of such fact in writing.

6.9 Governing Law. This Assignment shall be governed by and construed in accordance with the patent laws of the United States of America and with the internal laws of the State of Wisconsin.


IN WITNESS WHEREOF, this Assignment has been duly executed by the parties hereto as of the date first written above.


ASSIGNOR:

ASSIGNEE:

NATIONAL CANCER CENTER

EUTILEX CO., LTD.

By: 
Name: Chang Jie Woo
Title: Chief of OTT

By: 
Name: Bouny S. Kwon
Title: CEO

APPENDIX A

LIST OF THE ASSIGNED PATENTS

Title of Patent/ Publication	RBVD Ref.	E&L Ref.	Country	Publication/ Patent Number	Filing Date	Application Number	Reg. Date
ANTIBODY SPECIFICALLY RECOGNIZING AN EPITOPE FOR SWITCHING TO TH2 CELL AND A METHOD FOR CONVERTING T CELL TO TYPE 2 HELPER T CELL USING THE SAME	510395	OP1136636US	US	9,255,152	2013-04-12	13/861,675	2016-02-09
NOVEL EPITOPE FOR SWITCHING TO TH2 CELL AND USE THEREOF	510395-DIV	OP1136687US	US	US-2016-0046691	2015-06-15	14/739,763	-
MONOCLONAL ANTIBODY SPECIFICALLY RECOGNIZING AN EPITOPE FOR SWITCHING TO TH17 CELL	510396	OP1136635US	US	9,309,321	2013-04-12	13/861,619	2016-04-12
AN ANTIBODY SPECIFICALLY RECOGNIZING AN EPITOPE FOR SWITCHING TO TH1 CELL	510397	OP1136634US	US	9,255,151	2013-04-12	13/861,644	2016-02-09
NOVEL EPITOPE FOR SWITCHING TO TH1 CELL AND USE THEREOF	510397-DIV	OP1136686US	US	US-2016-0024177-A1	2015-06-15	14/739,770	-
MONOCLONAL ANTIBODY WHICH SPECIFICALLY RECOGNIZES B CELL LYMPHOMA AND USE THEREOF	510457	OP1136644US	US	-	2015-03-05	14/639,679	-
NOVEL EPITOPE FOR SWITCHING TO TH17 CELL AND USE THEREOF	510396-DIV	OP1136789US	US	US-2016-0244503-A1	2016-02-25	15/053,360	-

MWV1009243A1P:JMM 08/20/03
34220873